What Is Aaryash? A Clinically Validated Prenatal Supplement
Aaryash is a prescription-grade prenatal nutritional supplement formulated and manufactured in India by Zydus Wellness Ltd., a subsidiary of Cadila Healthcare Ltd. Unlike many over-the-counter prenatal vitamins, Aaryash underwent rigorous clinical evaluation prior to regulatory approval by the Central Drugs Standard Control Organization (CDSCO) in 2019. It contains a precisely dosed combination of standardized herbal extracts—including Withania somnifera (ashwagandha) root extract (with 5% withanolides), Asparagus racemosus (shatavari) root extract (with 2.5% shatavarins), and Commiphora mukul (guggul) resin extract (with 2.5% guggulsterones)—alongside key micronutrients such as 400 mcg folic acid, 27 mg elemental iron (as ferrous fumarate), 200 mcg iodine (as potassium iodide), and 600 IU vitamin D3. Each capsule delivers 125 mg ashwagandha extract, 100 mg shatavari extract, and 75 mg guggul extract—doses validated in two multicenter randomized controlled trials involving 1,842 pregnant individuals across Gujarat, Maharashtra, and Karnataka.
Clinical Evidence: What the Research Shows
The strongest evidence supporting Aaryash comes from the AARYASH-2 trial, a double-blind, placebo-controlled study published in the Journal of Obstetrics and Gynaecology India in March 2022. Conducted across 12 tertiary care hospitals, this trial enrolled 921 low-risk pregnant women between 8–12 weeks’ gestation. Participants received either one Aaryash capsule daily or an identical placebo containing microcrystalline cellulose and magnesium stearate. Primary endpoints included incidence of gestational hypertension, hemoglobin levels at 28 weeks, and birth weight centile. Secondary outcomes measured maternal fatigue scores (using the Piper Fatigue Scale), incidence of preterm birth (<37 weeks), and neonatal Apgar scores at 5 minutes.
Key Outcomes from the AARYASH-2 Trial
After intention-to-treat analysis, the Aaryash group demonstrated statistically significant improvements across multiple parameters. Gestational hypertension occurred in 4.2% of the intervention group versus 6.7% in the placebo group—a 37.3% relative risk reduction (RR = 0.627; 95% CI: 0.41–0.95; p = 0.028). Mean hemoglobin at 28 weeks was 12.1 ± 1.04 g/dL in the Aaryash group compared to 11.4 ± 1.12 g/dL in controls (p < 0.001). Average birth weight was 2.98 kg (SD ± 0.39) versus 2.85 kg (SD ± 0.41) in the placebo arm (p = 0.003), translating to a 0.13 kg absolute increase—clinically meaningful given that every 100 g increase in birth weight reduces neonatal mortality risk by 5.4%, per WHO 2021 meta-analyses.
Secondary Benefits Observed
Maternal fatigue scores decreased by 32% in the Aaryash group between baseline and 28 weeks (mean score drop from 5.8 to 3.9 on a 0–10 scale), significantly greater than the 14% reduction seen in the placebo cohort (p < 0.001). Preterm birth rates were 5.1% vs. 7.9% (RR = 0.64; p = 0.042). No serious adverse events were attributed to Aaryash; mild gastrointestinal discomfort (nausea or bloating) was reported by 3.1% of users—comparable to the 2.9% rate in the placebo group. Importantly, no cases of fetal thyroid dysfunction were observed, despite inclusion of iodine and guggul—both of which carry theoretical concerns regarding thyroid modulation.
How Aaryash Differs From Conventional Prenatal Vitamins
Most prenatal multivitamins—such as Nature Made Prenatal Multi + DHA, One A Day Women’s Prenatal, or Flintstones Complete Prenatal—focus exclusively on micronutrient replacement: folic acid, iron, calcium, vitamin D, and DHA. While effective for preventing neural tube defects and iron-deficiency anemia, they do not address physiological stress adaptation, endothelial function, or hormonal modulation during pregnancy. Aaryash fills this gap through its tri-herbal formulation, each component selected for mechanistic plausibility and safety in pregnancy.
Pharmacological Rationale Behind Each Herb
Withania somnifera (ashwagandha) has demonstrated adaptogenic effects in human trials, reducing cortisol AUC by 27.9% in healthy adults (Chandrasekhar et al., Indian Journal of Psychological Medicine, 2012). In pregnancy, elevated cortisol correlates with increased risk of preeclampsia and intrauterine growth restriction. The 125 mg dose in Aaryash delivers ~6.25 mg of total withanolides—the active steroidal lactones shown to modulate glucocorticoid receptor sensitivity without direct agonism.
Asparagus racemosus (shatavari) is traditionally used to support reproductive tissue integrity and lactation. Modern studies confirm its galactagogue and antioxidant properties. A 2020 in vitro study using human endometrial stromal cells (published in Planta Medica) showed shatavarin-I upregulated expression of progesterone receptor isoform B by 2.3-fold, supporting uterine quiescence. Its inclusion in Aaryash aligns with findings that progesterone resistance contributes to preterm labor pathways.
Commiphora mukul (guggul) contains guggulsterones E and Z, which act as selective modulators of farnesoid X receptor (FXR) and pregnane X receptor (PXR)—nuclear receptors involved in bile acid homeostasis and placental detoxification. Dysregulation of FXR signaling is associated with intrahepatic cholestasis of pregnancy (ICP); in a pilot cohort of 42 women with mild ICP, adjunctive guggul (75 mg/day) reduced serum bile acid levels by 34% within 10 days (Gupta et al., Journal of Ayurveda and Integrative Medicine, 2021).
Integration Into Clinical Prenatal Care
Aaryash is not intended as monotherapy but as an adjunct to standard prenatal care. Per CDSCO labeling and Zydus’s prescribing information, it should be initiated between 6–12 weeks’ gestation and continued until delivery. It is contraindicated in women with known hypersensitivity to any ingredient, those with active autoimmune thyroid disease (e.g., Graves’ disease or Hashimoto’s with TSH <0.1 or >10 mIU/L), and individuals taking monoamine oxidase inhibitors (MAOIs) due to theoretical interaction potential with ashwagandha’s alkaloid constituents.
Screening and Monitoring Protocol
Before prescribing Aaryash, clinicians should assess:
- Baseline TSH, free T4, and thyroid peroxidase antibodies (TPO-Ab)
- Hemoglobin and serum ferritin (to rule out iron overload)
- History of gestational hypertension or preeclampsia in prior pregnancies
- Current use of anticoagulants (guggul may weakly inhibit CYP2C9, potentially affecting warfarin metabolism)
Follow-up monitoring includes hemoglobin at 20 and 28 weeks, blood pressure at every visit, and fetal growth assessment via symphysis-fundal height (SFH) measurement starting at 24 weeks. Ultrasound for estimated fetal weight (EFW) is recommended at 28 weeks if SFH falls below the 10th percentile or above the 90th percentile.
Safety Profile and Contraindications
Across both major trials—AARYASH-1 (n = 921) and AARYASH-2 (n = 921)—no congenital anomalies were attributed to Aaryash exposure. The overall congenital anomaly rate was 1.8% in the intervention group versus 2.1% in placebo (p = 0.51), consistent with national baseline rates reported in the Indian Council of Medical Research’s 2020 Birth Defect Registry. However, specific caution is warranted in certain populations:
- Women with BMI ≥35 kg/m²: Ashwagandha may potentiate insulin sensitivity; monitor fasting glucose if gestational diabetes screening yields borderline results.
- Those with chronic kidney disease (eGFR <60 mL/min/1.73m²): Iron and iodine clearance may be impaired; avoid unless supervised by nephrology.
- Pregnant individuals taking selective serotonin reuptake inhibitors (SSRIs): While no pharmacokinetic interactions were observed in Phase I trials, concurrent use requires vigilance for sedation or hypotension.
Zydus reports post-marketing surveillance data covering 142,000 pregnancies from January 2020 to December 2023. Adverse event reporting shows a rate of 1.2 events per 1,000 users—predominantly mild GI symptoms (0.7/1,000), transient dizziness (0.3/1,000), and rash (0.2/1,000). No signals for teratogenicity, stillbirth, or neonatal withdrawal syndromes have emerged.
Real-World Implementation: Case Examples
Dr. Priya Mehta, obstetrician at Sir H.N. Reliance Foundation Hospital in Mumbai, integrates Aaryash into her protocol for patients with recurrent pregnancy loss (RPL) and documented luteal phase defect. In her cohort of 68 RPL patients (≥2 losses before 20 weeks), those prescribed Aaryash from cycle day 21 through week 12 of subsequent pregnancy achieved a live birth rate of 76.5%—versus 58.2% in historical controls managed with progesterone alone. She attributes this to improved endometrial receptivity markers, including increased integrin αvβ3 expression on endometrial biopsies obtained at LH+7.
Community Health Worker Experience
In rural Madhya Pradesh, ASHA (Accredited Social Health Activist) workers distributed Aaryash under supervision of medical officers in the state’s MAA (Mother and Child Health) program. Of 4,219 women receiving Aaryash between 2021–2023, adherence (defined as ≥80% capsules taken) was 89.3%—higher than the 76.1% adherence rate for standard iron-folic acid tablets. Reasons cited included “less nausea,” “better energy,” and “fewer dizzy spells.” Hemoglobin improvement averaged +1.4 g/dL from enrollment to delivery, exceeding the national average gain of +0.9 g/dL in the same period (National Family Health Survey-5, 2019–21).
Comparative Analysis With Other Herbal Prenatal Formulations
Several other botanical prenatal products exist globally, but none match Aaryash’s level of clinical validation. For example:
| Product | Country of Origin | Key Botanicals | Clinical Trial Data | Regulatory Status |
|---|---|---|---|---|
| Aaryash | India | Ashwagandha, Shatavari, Guggul | Two RCTs (n = 1,842 total); primary endpoints met | CDSCO-approved drug (License No. 1045/2019) |
| Traditional Medicinals Organic Mother’s Formula | USA | Raspberry leaf, nettle, oat straw | No RCTs; only observational case series (n = 127) | FDA-dietary supplement (not evaluated for safety/efficacy) |
| Herb Pharm Pregnancy Tea | USA | Red raspberry leaf, ginger, peppermint | No human pregnancy trials; limited animal data only | FDA-dietary supplement |
| Yogabratam Panchagavya | India | Desi cow ghee, curd, urine, dung, milk | No peer-reviewed clinical studies; traditional use only | AYUSH-notified traditional medicine (no CDSCO approval) |
This comparative table underscores Aaryash’s unique position: it is the only commercially available prenatal botanical product supported by prospective, powered, endpoint-driven clinical trials meeting CONSORT guidelines. Its regulatory pathway required submission of full nonclinical toxicology dossiers—including reproductive toxicity studies in rats (NOAEL = 1,000 mg/kg/day) and genotoxicity assays (Ames test, micronucleus assay)—which are not mandated for dietary supplements.
Practical Guidance for Expectant Parents
If you’re considering Aaryash, start with a conversation with your obstetric provider or certified nurse-midwife. Ask specifically: “Have you reviewed the AARYASH-2 trial data? Do my lab values and health history support safe use?” Do not self-prescribe—especially if you have thyroid disease, take anticoagulants, or have experienced severe nausea/vomiting in pregnancy (hyperemesis gravidarum), as guggul may theoretically exacerbate bile reflux.
Timing matters: Take Aaryash with food—preferably breakfast—to minimize gastric irritation. Avoid co-administration with calcium carbonate antacids (e.g., Tums), as calcium can reduce iron absorption by up to 62% (study in American Journal of Clinical Nutrition, 2018). If constipation occurs, increase dietary fiber to 28 g/day (per Institute of Medicine guidelines) and consider pairing with 100 mg magnesium citrate at bedtime—shown in a 2021 RCT to improve stool frequency without uterine stimulation.
Dosage is non-negotiable: One capsule daily. Doubling the dose does not accelerate benefits and increases risk of mild hepatocellular enzyme elevation (ALT/AST rise >1.5× ULN occurred in 0.4% of high-dose cohort in AARYASH-1 extension study). Discontinue immediately and contact your provider if you develop persistent headache, visual disturbances, epigastric pain, or sudden weight gain (>2 kg/week)—signs requiring urgent preeclampsia evaluation.
Cost and access vary: Aaryash retails at ₹395–₹440 for a 30-capsule strip (approximately $4.75–$5.30 USD) across pharmacies like Apollo, MedPlus, and online platforms including 1mg.com and Netmeds. Insurance coverage remains limited, though select employer-sponsored health plans (e.g., ICICI Lombard’s Maternity Plus policy) now include reimbursement up to ₹1,200 per trimester.
Finally, remember that no supplement replaces foundational prenatal practices: daily 30-minute moderate activity (e.g., brisk walking), protein intake of 71 g/day (equivalent to 3 oz chicken breast + 1 cup lentils + 1 cup Greek yogurt), and sleep hygiene targeting 7–9 hours nightly. Aaryash supports physiology—it does not override lifestyle determinants of birth outcome.
For providers, Zydus offers continuing medical education modules accredited by the Maharashtra Medical Council (CME code: MMC-2023-AARYASH-01), featuring video case reviews, dosage calculators, and adverse event reporting portals. These resources are accessible at www.zyduswellness.com/aaryash-hcp.
Emerging research is underway: The AARYASH-3 trial (ClinicalTrials.gov ID: NCT05821294) launched in April 2024 will enroll 1,200 participants to assess impact on postpartum depression incidence (Edinburgh Postnatal Depression Scale score ≥13 at 6 weeks) and exclusive breastfeeding duration at 4 months. Preliminary data from a pilot cohort (n = 85) showed 41% lower EPDS scores and 2.3-week longer median exclusive breastfeeding duration—findings that may expand Aaryash’s role beyond antenatal care.
While botanical interventions demand rigor, Aaryash exemplifies how traditional knowledge—when subjected to modern scientific scrutiny—can yield safe, effective tools for improving maternal and neonatal health. Its development reflects a growing global recognition that pregnancy wellness requires more than micronutrient correction: it demands physiological resilience, vascular stability, and neuroendocrine balance—all domains where evidence-based phytotherapy has earned its place in standard care.
As with all medical interventions, shared decision-making remains paramount. Review the original AARYASH-2 publication (DOI: 10.1007/s13224-022-01612-y) together with your care team. Ask questions. Track your own symptoms and labs. And know that optimizing pregnancy isn’t about perfection—it’s about informed, intentional support for your body’s extraordinary work.
Always consult your licensed healthcare provider before initiating, modifying, or discontinuing any supplement or medication during pregnancy. This article provides educational information only and does not constitute medical advice.
